New drug indication approval - June 2020

Product Name

ADCETRIS POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/VIAL

Active Ingredient

Brentuximab Vedotin

Product Registrant

TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.

Date of Approval

22/06/2020

Indications:

Frontline systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), in combination with chemotherapy

ADCETRIS is indicated for the treatment of patients with CD30-expressing previously untreated peripheral T-cell lymphoma (PTCL) in combination with chemotherapy.

Product Name

LUCENTIS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 1.65MG/0.165ML

LUCENTIS 10MG/ML SOLUTION FOR INJECTION

Active Ingredient

Ranibizumab

Product Registrant

NOVARTIS (SINGAPORE) PTE LTD

Date of Approval

26/06/2020

Indications:

Lucentis is indicated for: the treatment of proliferative diabetic retinopathy (PDR)